Posted in M&A / Deals Lilly to acquire CrossBridge Bio for up to $300m April 15, 2026 Pharmaceutical Business Review The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer. M&A / DealsRead full story